FDA Orange Book · active-ingredient family
Arformoterol tartrate
Arformoterol tartrate is approved as 1 brand and 17 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:BROVANA · NDA 021912
1
Brand (NDA)
17
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| BROVANARLD | LUPIN | NDA 021912 | — | Oct 06, 2006 |
Generic (ANDA) products (17)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ARFORMOTEROL TARTRATE | SABA ILAC SANAYI | ANDA 218429 | AN | Apr 25, 2025 | |
| ARFORMOTEROL TARTRATE | MICRO LABS | ANDA 218555 | AN | Mar 07, 2025 | |
| ARFORMOTEROL TARTRATE | AUCTA | ANDA 218380 | AN | Feb 03, 2025 | |
| ARFORMOTEROL TARTRATE | LEXENPHARM | ANDA 218156 | AN | Nov 18, 2024 | |
| ARFORMOTEROL TARTRATE | DR REDDYS | ANDA 215032 | AN | Jun 03, 2024 | |
| ARFORMOTEROL TARTRATE | NEOCUBES PHARMA | ANDA 216303 | AN | May 17, 2024 | |
| ARFORMOTEROL TARTRATE | AIPING PHARM INC | ANDA 214901 | AN | Apr 02, 2024 | |
| ARFORMOTEROL TARTRATE | WILSHIRE PHARMS INC | ANDA 216815 | AN | Nov 25, 2022 | |
| ARFORMOTEROL TARTRATE | MANKIND PHARMA | ANDA 216128 | AN | Nov 15, 2022 | |
| ARFORMOTEROL TARTRATE | SUN PHARM | ANDA 215385 | AN | May 26, 2022 | |
| ARFORMOTEROL TARTRATE | ALEMBIC | ANDA 214779 | AN | May 10, 2022 | |
| ARFORMOTEROL TARTRATE | RITEDOSE CORP | ANDA 214736 | AN | Mar 02, 2022 | |
| ARFORMOTEROL TARTRATE | LUPIN | ANDA 213068 | AN | Feb 07, 2022 | |
| ARFORMOTEROL TARTRATE | TEVA PHARMS USA | ANDA 200293 | AN | Nov 09, 2021 | |
| ARFORMOTEROL TARTRATE | CIPLA | ANDA 207306 | AN | Jun 22, 2021 | |
| ARFORMOTEROL TARTRATE | GLENMARK PHARMS LTD | ANDA 213132 | — | Jun 22, 2021 | |
| ARFORMOTEROL TARTRATE | SLATE RUN PHARMA | ANDA 213762 | AN | Jun 22, 2021 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Arformoterol tartrate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
